Reuters: Regulatory News: Lilly's Alimta combination cancer therapy fails trial

Reuters: Regulatory News Reuters.com is your source for breaking news, business, financial and investing news, including personal finance and stocks. Reuters is the leading global provider of news, financial information and technology solutions to the world's media, financial institutions, businesses and individuals. // via fulltextrssfeed.com

Lilly's Alimta combination cancer therapy fails trial Sep 6th 2012, 13:33 Sept 6 | Thu Sep 6, 2012 9:33am EDT Sept 6 (Reuters) - Eli Lilly and Co said a late-stage trial testing its lung cancer drug Alimta failed to meet the main study goal of improving overall survival of patients. Patients on the trial, named Pointbreak, were given either a combination of Alimta and Roche Holding AG's cancer drug Avastin along with chemotherapy, or just Avastin along with chemotherapy drugs.

You are receiving this email because you subscribed to this feed at blogtrottr.com. If you no longer wish to receive these emails, you can unsubscribe from this feed, or manage all your subscriptions